^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Cejemly (sugemalimab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    CStone Pharma Press Release
    Title:

    CStone Announces Registrational Trial of Sugemalimab in First-line Gastric or Gastroesophageal Junction Adenocarcinoma Met Primary Endpoint of Overall Survival

    Published date:
    08/29/2023
    Excerpt:
    CStone Pharmaceuticals...announced that the Phase 3 GEMSTONE-303 study met its primary endpoint of overall survival (OS). Sugemalimab in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvement in OS, compared with placebo plus chemotherapy, as a first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with PD-L1 expression ≥5%. The safety profile was consistent with previous reports of sugemalimab studies, and no new safety signals were identified.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

    Excerpt:
    ...Subject must provide tumor tissue samples for biomarker analysis in order to determine the expression of PD-L1....
    Trial ID:
    GEMSTONE-303